Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Michèle Boisdron-Celle"'
Autor:
Ke Zhou, Jean-Luc Raoul, Audrey Blanc-Lapierre, Valérie Seegers, Michèle Boisdron-Celle, Marianne Bourdon, Hakim Mahammedi, Aurélien Lambert, Camille Moreau-Bachelard, Mario Campone, Thierry Conroy, Frédérique Penault-Llorca, Martine M Bellanger, Frédéric Bigot
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 16 (2022)
Background: Cancer patients (CPs) are considered more vulnerable and as a high mortality group regarding COVID-19. In this analysis, we aimed to describe asymptomatic COVID (+) CPs and associated factors. Methods: We conducted a prospective study in
Externí odkaz:
https://doaj.org/article/c904ab906e364ff9a913c197daea705d
Autor:
Laure Moisset, Judith Raimbourg, Sandrine Hiret, Jonathan Dauve, Michèle Boisdron-Celle, Hélène Senellart, Jean-Luc Raoul
Publikováno v:
Case Reports in Oncology, Vol 12, Iss 2, Pp 426-429 (2019)
We report the case of a 32-year-old man with a caecal adenocarcinoma with major lymph node extension and peritoneal carcinomatosis, presenting a BRAF-K601E mutation. A triplet (5FU plus oxaliplatin plus irinotecan) combination with bevacizumab achiev
Externí odkaz:
https://doaj.org/article/2ae4bd1e174f474ca23c19624c2e531c
Autor:
Valérie Seegers, Guillaume Rousseau, Ke Zhou, Audrey Blanc-Lapierre, Frédéric Bigot, Hakim Mahammedi, Aurélien Lambert, Camille Moreau-Bachelard, Mario Campone, Thierry Conroy, Frédérique Penault-Llorca, Michèle Boisdron-Celle, Martine Bellanger, Jean-Luc Raoul
Publikováno v:
Cancers; Volume 14; Issue 22; Pages: 5547
In this prospective, real-life cohort study, we followed 523 cancer patients (CP) and 579 healthcare workers (HCW) from two cancer centers to evaluate the biological and clinical results of the COVID-19 vaccination campaign. Seventy percent of the CP
Autor:
Ke Zhou, Jean-Luc Raoul, Audrey Blanc-Lapierre, Valérie Seegers, Michèle Boisdron-Celle, Marianne Bourdon, Hakim Mahammedi, Aurélien Lambert, Camille Moreau-Bachelard, Mario Campone, Thierry Conroy, Frédérique Penault-Llorca, Martine M Bellanger, Frédéric Bigot
Publikováno v:
Clinical Medicine Insights: Oncology
Clinical Medicine Insights: Oncology, SAGE, 2022, 16, pp.117955492210901. ⟨10.1177/11795549221090187⟩
Clinical Medicine Insights: Oncology, 2022, 16, pp.117955492210901. ⟨10.1177/11795549221090187⟩
Clinical Medicine Insights: Oncology, SAGE, 2022, 16, pp.117955492210901. ⟨10.1177/11795549221090187⟩
Clinical Medicine Insights: Oncology, 2022, 16, pp.117955492210901. ⟨10.1177/11795549221090187⟩
Background:Cancer patients (CPs) are considered more vulnerable and as a high mortality group regarding COVID-19. In this analysis, we aimed to describe asymptomatic COVID (+) CPs and associated factors.Methods:We conducted a prospective study in CPs
Autor:
Michèle Boisdron-Celle, Valérie Seegers, Aurélien Lambert, Mario Campone, Audrey Blanc-Lapierre, Ke Zhou, Marianne Bourdon, Jean-Luc Raoul, Frédéric Bigot, Martine Bellanger, Hakim Mahammedi, Thierry Conroy, Frédérique Penault-Llorca
Publikováno v:
Cancers
Cancers, 2021, 13 (14), pp.3389. ⟨10.3390/cancers13143389⟩
Cancers, MDPI, 2021, 13 (14), pp.3389. ⟨10.3390/cancers13143389⟩
Cancers, Vol 13, Iss 3389, p 3389 (2021)
Volume 13
Issue 14
Cancers, 2021, 13 (14), pp.3389. ⟨10.3390/cancers13143389⟩
Cancers, MDPI, 2021, 13 (14), pp.3389. ⟨10.3390/cancers13143389⟩
Cancers, Vol 13, Iss 3389, p 3389 (2021)
Volume 13
Issue 14
Simple Summary COVID-19 has some clinical manifestations that are similar to the side effects of cancer treatments such that cancer patients may fail to distinguish COVID-19 symptoms from those of their treatments. The PAPESCO-19 study investigated 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88fad0488e032550f9bb4d4332308410
https://hal.science/hal-03299068/file/cancers-13-03389.pdf
https://hal.science/hal-03299068/file/cancers-13-03389.pdf
Autor:
Bourdon M, Blanc-Lapierre A, Mahammedi H, Seegers, Bigot F, Zhou K, Lambert A, Michèle Boisdron-Celle, Campone M, Jean-Luc Raoul, Bellanger M
Background: Cancer patients may fail to distinguish COVID-19 symptoms such as anosmia, dysgeusia/ageusia, anorexia, headache, and fatigue, which are frequent after cancer treatments. We aimed to identify symptoms associated with COVID-19 and to asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2d281f3f1685cff0f98f6a0f6004088
https://doi.org/10.20944/preprints202103.0292.v1
https://doi.org/10.20944/preprints202103.0292.v1
Autor:
M. Caulet, Olivier Capitain, Nicolas Azzopardi, Thierry Lecomte, David Tougeron, D. Ternant, Romain Chautard, G. Paintaud, Michèle Boisdron-Celle, C. Passot, S. Lobet, C. Vignault-Desvignes
Publikováno v:
Annals of Oncology. 32:S547
Autor:
Ludovic Rosenfeld, Virginie Berger, Erick Gamelin, Karine Bouhier-Leporrier, Claire Stampfli, Isabelle Baumgaertner, Thierry Lecompte, Mehdi Kaassis, Eric Francois, Christophe Borg, Alain Morel, Celia Roemer-Becuwe, Veronique Guerin-Meyer, Roger Faroux, Michèle Boisdron-Celle, Oana Cojocarasu, Jean Philippe Metges, Olivier Capitain, Marie Pierre Galais, Jaafar Bennouna
Publikováno v:
Seminars in Oncology. 44:13-23
5-Fluorouracil (5-FU)–based treatments can lead to early-onset severe (4%–5%) even fatal (0.3%) toxicities in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This multicenter prospective cohort study aimed to assess the clinical b
Autor:
Michèle Boisdron-Celle, Claude Masliah, Antoine Adenis, Jean Philippe Metges, Olivier Capitain, Virginie Berger, You Heng Lam, Jean-Luc Raoul, Erick Gamelin, Roger Faroux, Anne Lise Poirier, Thierry Lecomte, Alain Morel
Publikováno v:
Seminars in Oncology
Seminars in Oncology, WB Saunders, 2017, 44 (1), pp.24-33. ⟨10.1053/j.seminoncol.2017.02.007⟩
Seminars in Oncology, 2017, 44 (1), pp.24-33. ⟨10.1053/j.seminoncol.2017.02.007⟩
Seminars in Oncology, WB Saunders, 2017, 44 (1), pp.24-33. ⟨10.1053/j.seminoncol.2017.02.007⟩
Seminars in Oncology, 2017, 44 (1), pp.24-33. ⟨10.1053/j.seminoncol.2017.02.007⟩
International audience; We conducted a multicenter proof of concept phase II trial in patients with advanced colorectal cancer receiving FOLFIRI-cetuximab regimens to explore individual drug tailoring using pharmacogenetics and pharmacokinetics (PK)
Autor:
J.-P. Metges, P. Laplaige, M. Campone, Alain Morel, M. Ferec, Claire Stampfli, Olivier Capitain, Thierry Lecomte, E. Gamelin, Tamara Matysiak-Budnik, Roger Faroux, Hélène Senellart, Michèle Boisdron-Celle
Publikováno v:
Annals of Oncology. 29:v60-v61